Company / Cash & Equivalents
PACS Group, Inc. Cash & Equivalents History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$197.0M
FY2025
5-year range
$58.3M / $197.0M
FY2022-FY2025
Trend
+25.0%
vs FY2024
Sector context
#82 of 148
Health Care
What the data says
At $197M, PACS Group, Inc.'s cash & equivalents ranks #82 of 148 in the Health Care sector. Cash & Equivalents has increased for 3 consecutive years, from $58M in FY2022 to $197M in FY2025.
Based on SEC 10-K filings.
$197M in FY2025 with a 3-year CAGR of +50.1%.
Improved from $73M to $197M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +50.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#82 of 148 in Health CareTop 55% of 148This company $197.0M Sector average $1.2B
▼
-83.3% below sector average
Key checks
Key Insights
- PACS Group, Inc.'s cash & equivalents has grown for 3 consecutive years.
- 3-year CAGR of +50.1%, indicating consistent growth.
- In FY2025, cash & equivalents increased 25.0% year-over-year.
- Ranks #82 out of 148 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $197.0M | +25.0% |
| FY2024 | $157.7M | +114.8% |
| FY2023 | $73.4M | +26.0% |
| FY2022 | $58.3M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026